OMNIAB INC (OABI)
US68218J1034 - Common Stock
Taking everything into account, OABI scores 4 out of 10 in our fundamental rating. OABI was compared to 55 industry peers in the Life Sciences Tools & Services industry. While OABI has a great health rating, there are worries on its profitability. OABI is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year OABI has reported negative net income.
OABI had a negative operating cash flow in the past year.
OABI had negative earnings in each of the past 5 years.
In multiple years OABI reported negative operating cash flow during the last 5 years.
1.2 Ratios
OABI has a Return On Assets (-18.50%) which is in line with its industry peers.
OABI has a Return On Equity of -21.21%. This is comparable to the rest of the industry: OABI outperforms 49.09% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -18.5% | ||
| ROE | -21.21% | ||
| ROIC | N/A |
ROA(3y)-9.22%
ROA(5y)N/A
ROE(3y)-11.39%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for OABI so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
OABI does not have a ROIC to compare to the WACC, probably because it is not profitable.
OABI has more shares outstanding than it did 1 year ago.
There is no outstanding debt for OABI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
OABI has an Altman-Z score of 6.74. This indicates that OABI is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 6.74, OABI belongs to the best of the industry, outperforming 83.64% of the companies in the same industry.
There is no outstanding debt for OABI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 6.74 |
ROIC/WACCN/A
WACC10.34%
2.3 Liquidity
A Current Ratio of 4.75 indicates that OABI has no problem at all paying its short term obligations.
OABI has a better Current ratio (4.75) than 69.09% of its industry peers.
A Quick Ratio of 4.75 indicates that OABI has no problem at all paying its short term obligations.
OABI has a better Quick ratio (4.75) than 78.18% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.75 | ||
| Quick Ratio | 4.75 |
3. Growth
3.1 Past
The earnings per share for OABI have decreased strongly by -149.13% in the last year.
Looking at the last year, OABI shows a very negative growth in Revenue. The Revenue has decreased by -67.16% in the last year.
OABI shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.66% yearly.
EPS 1Y (TTM)-149.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.33%
Revenue 1Y (TTM)-67.16%
Revenue growth 3Y13.66%
Revenue growth 5YN/A
Sales Q2Q%9.62%
3.2 Future
The Earnings Per Share is expected to grow by 8.99% on average over the next years. This is quite good.
The Revenue is expected to grow by 21.52% on average over the next years. This is a very strong growth
EPS Next Y-10.13%
EPS Next 2Y11.79%
EPS Next 3Y14.85%
EPS Next 5Y8.99%
Revenue Next Year-15.35%
Revenue Next 2Y20.58%
Revenue Next 3Y24.64%
Revenue Next 5Y21.52%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
OABI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OABI. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as OABI's earnings are expected to grow with 14.85% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.79%
EPS Next 3Y14.85%
5. Dividend
5.1 Amount
OABI does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
OMNIAB INC
NASDAQ:OABI (11/12/2024, 8:22:16 PM)
After market: 4.15 -0.34 (-7.57%)4.49
-0.11 (-2.39%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap530.54M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -18.5% | ||
| ROE | -21.21% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.06
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.75 | ||
| Quick Ratio | 4.75 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-149.13%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-10.13%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-67.16%
Revenue growth 3Y13.66%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y